Schizophrenia Survey Reveals Gaps That Echo Across Psychiatry

What the SPAN Survey Found

A newly published survey from the Schizophrenia and Psychosis Action Network (SPAN) is drawing attention to a stubborn paradox in modern psychiatric care: treatment options are advancing faster than the systems meant to deliver them. Despite the emergence of newer antipsychotic medications and a growing clinical understanding of schizophrenia's complexity, the survey found that patients continue to face significant barriers around insurance coverage, care continuity, and access to specialists — obstacles that often negate the theoretical promise of improved treatments.

The survey, covered by Psychiatric Times, highlighted that coverage denials, prior authorization hurdles, and fragmented handoffs between care settings remain widespread. Patients who do access newer treatments often struggle to stay on them due to cost or gaps in follow-up care. Clinicians reported frustration with payer policies that lag far behind clinical guidelines.

Why This Matters Beyond Schizophrenia

For readers of Ketamine Resource, schizophrenia treatment may seem like a distant topic — and in one important sense, it is. Ketamine is not a treatment for schizophrenia or psychotic disorders. In fact, because ketamine can exacerbate psychotic symptoms, it is generally contraindicated for people with a history of schizophrenia or other primary psychotic conditions. Any patient with that history should discuss it openly with a provider before pursuing ketamine therapy.

That said, the structural problems the SPAN survey describes are not unique to schizophrenia. They represent a systemic pattern that runs through nearly every corner of psychiatric care — including the world of ketamine and esketamine treatment. The same forces that create coverage gaps for antipsychotics are at work when insurers decline to cover IV ketamine infusions, impose narrow criteria for Spravato (esketamine) authorization, or require patients to cycle through multiple failed antidepressants before qualifying for newer interventions.

The survey's findings on care continuity are particularly resonant. Ketamine treatment, especially for treatment-resistant depression, depends heavily on consistent follow-up. A patient who gets an initial infusion series but loses access to a prescriber, can't afford maintenance sessions, or gets caught in a prior authorization loop faces the same kind of disruption the SPAN respondents described — progress stalled not by clinical failure, but by system failure.

The Bigger Picture: Innovation Without Access Is Not Progress

One of the clearest themes from the SPAN survey is that a more sophisticated treatment landscape does not automatically translate into better outcomes. This is a pattern psychiatry keeps relearning. Clozapine, one of the most effective antipsychotics ever developed, remains chronically underutilized due to monitoring requirements and prescriber hesitancy. Esketamine received FDA approval for treatment-resistant depression in 2019, yet remains out of reach for many patients who could benefit, largely due to cost and restricted insurance coverage. The treatments exist; the infrastructure to deliver them equitably does not.

For patients and families navigating the mental health system, these findings reinforce a practical reality: finding an effective treatment is often only the first hurdle. Sustaining access to it — through insurance approvals, provider continuity, and financial feasibility — is a separate and often harder challenge.

For clinicians and advocates, the survey adds to a growing body of evidence that payer reform, streamlined prior authorization processes, and better care coordination are not administrative footnotes. They are clinical necessities. Treatments that work in trials but fail in practice due to access barriers are not fully realized treatments.

What to Watch Going Forward

The SPAN survey arrives at a moment when federal attention to mental health parity enforcement is higher than it has been in years, with recent regulatory activity pushing insurers to justify coverage denials for mental health treatments more rigorously than in the past. Whether that pressure translates into meaningful change for patients — with schizophrenia, treatment-resistant depression, or any other psychiatric condition — remains to be seen.

What is clear is that surveys like this one serve an important function: they put data behind what patients and clinicians already know from experience, and they create pressure points for policy change. The ketamine community has its own version of this work to do. Better documentation of access barriers, outcome data from real-world patients, and organized advocacy around coverage criteria will all be necessary to move the needle on what is currently a patchwork and often inequitable access landscape for one of the more promising tools in psychiatric medicine.